Möchten Sie immer auf dem neuesten Stand bleiben?

OraSure Announces Fourth Quarter 2025 Financial Results

CHIHUAHUA, Mexico, Feb. 25, 2026 (GLOBE NEWSWIRE) -- GCC, S.A.B. de C.V. (BMV: GCC*), a leading company in the production of cement, aggregates and concrete in the United States and Mexico, today...

- Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company’s ambitions to expand its commercialisation activities and advance its...

MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anywhere Assurance today announced the launch of its new Anywhere America International Travel Medical Insurance plans, officially entering the global travel...

Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX)...

INCLINE VILLAGE, Nev., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tri Pointe Homes, Inc. (the “Company”) (NYSE: TPH) today announced results for the fourth quarter ended December 31, 2025 and full year 2025....

RNA-Based Therapeutics and Vaccines Market size was valued at US$ 1,285.10 Million in 2024, expanding at a CAGR of 5.50% from 2025 to 2032.

Jointly evaluate the synergistic therapeutic potential of JS207 (PD-1/VEGF BsAb) and ATG-037 (oral small-molecule CD73 inhibitor)

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery...